AiPharma Rebrands as Cellvera

Cellvera is working to develop antiviral solutions against SARS-CoV-2 and other viruses.

By: Kristin Brooks

Managing Editor, Contract Pharma

AiPharma, a global biopharmaceutical company developing innovative antiviral therapies, has completed a rebranding effort in response to company growth and to reflect its expanded business strategy. The company has relaunched under the brand name Cellvera.
 
This transformation is the result of a redefined strategy that in addition to Cellvera’s exiting flagship, the antiviral portfolio expands its focus on diversified, innovative therapies and other treatment solutions for rare and difficult-to-treat illnesses.
 
Cellvera aims to build a strong footprint in the space of virology, immunology, precision medication, and genetics, improving the lives of patients worldwide.
 
Cellvera aspires to be at the forefront of pioneering integrated Artificial Intelligence discovery, manufacturing, and distribution platforms in bioscience.
 
As part of Cellvera’s expanded strategic goals the company appointed Dr. Ashraf Allam as Executive Chairman.
 
Dr. Allam has more than 30 years of experience in the life science industry across the globe. He served as the CEO of the Pharmaceutical Investment Company, which is wholly owned by the (KSA) Kingdom of Saudi Arabia Public Investment Fund (PIF), a global investment powerhouse and one of the most significant sovereign wealth funds in the world, with assets of more than $500 billion. Before that, Ashraf held several executive regional and global roles in large multinationals, in both listed and privately-owned companies, including Mundipharma, Amgen, Johnson & Johnson, Eli Lilly & Company, and Bristol Myers Squibb; he played a strategic role in setting up and managing their business.
 
Alessandro Gadotti, CEO of Cellvera, said: “This is a very exciting time for the Cellvera team, and with Ashraf on board, I am confidently looking forward to achieving our goals and fulfilling the vision of building a robust global biopharma powerhouse ready to take the healthcare to another level. I strongly believe this is possible to achieve through the combination of science, AI, and digital diagnostics and technology, as well as through the unique partnerships with the top-tier allies pioneering the healthcare solutions of the new era.”
 
Cellvera is working to develop effective antiviral solutions against SARS-CoV-2 and other viruses and will continue working with their existing and future partners to accomplish this.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters